TWA
PGNX

TCI Wealth Advisors’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

TCI Wealth Advisors’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-53
Closed -$1K – 1403
2017
Q1 		$1K Buy
+53
New +$529 ﹤0.01% 1230

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PFC
Phocas Financial Corp Alameda, California $637M AUM 39.08% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

TCI Wealth Advisors's PGNX Position: Q2 2017 in Review

TCI Wealth Advisors sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2017, closing a stake of 53 shares — an estimated $1K sold.

TCI Wealth Advisors first reported a position in PGNX in Q1 2017 and held it in 1 quarter. The position peaked at $1K in Q1 2017. 152 funds tracked by Wall St. Rank hold PGNX as of Q2 2017.

  • TCI Wealth Advisors reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • TCI Wealth Advisors sold 53 Progenics Pharmaceuticals Inc shares in Q2 2017, an estimated $1K.
  • TCI Wealth Advisors first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 1 quarter.
  • TCI Wealth Advisors's Progenics Pharmaceuticals Inc position peaked at $1K in Q1 2017.
  • 152 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2017.

Based on TCI Wealth Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.